Antimicrobial susceptibilities of Clostridium difficile isolated in Japan

Journal of Infection and Chemotherapy

Volumn 19, Issue 2, 2013, Pages 360-362

  Kunishima, Hiroyuki ^a,b,c   Chiba, Junichi ^b   Saito, Michiko ^a   Honda, Yoshihiro ^b   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sendai Kosei Hospital   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Antibiotic susceptibility; Clostridium difficile; Japan; Metronidazole; Vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; MINOCYCLINE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG MONITORING; HUMAN; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 84880700886     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0553-5     Document Type: Article

References (15)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-55.
2. Jang SS, Hansen LM, Breher JE, Riley DA, Magdesian KG, Madigan JE, et al. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis. 1997;25(suppl 2):S266-7.
3. Peláez T, Alcalá L, Alonso R, Rodríguez- Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002;46:1647-50.
4. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-90.
5. Peláez T, Alcalá L, Alonso R, Martín-López A, García-Arias V, Marín M, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother. 2005;49:1157-9.
6. Barbut F, Decré D, Burghoffer B, Lesage D, Delisle F, Lalande V, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother. 1999;43:2607-11.
7. Dworczyński A, Sokół B, Meisel-Mikołajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios. 1991;65:149-53.
8. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, M11-A7. 7th ed. Wayne: Clinical and Laboratory Standards Institute; 2007.
9. European Committee on Antimicrobial Susceptibility Testing. 2011. Clinical breakpoint tables, version 1.3. European Committee on Antimicrobial Susceptibility Testing, London. http://www.eucast.org/eucast-susceptibility- testing/breakpoints/. Accessed 21 February 2012.
10. Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents. 2002;20:270-4.
11. Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012;56:3943-9.
12. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008;52:4163-5.
13. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004;48:2280-2.
14. Bishara J, Bloch Y, Garty M, Behor J, Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis. 2006;54:141-4.
15. Oka K, Osaki T, Hanawa T, Kurata S, Okazaki M, Manzoku T, et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. J Clin Microbiol. 2012;50:915-21.